Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 35479.61 
• Atom Count: 2308 
• Residue Count: 308 
• Unique protein chains: 1

5E1S

The Crystal structure of INSR Tyrosine Kinase in complex with the Inhibitor BI 885578

• DOI: 10.2210/pdb5E1S/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda


• Deposited: 2015-09-30 Released: 2015-10-14 
• Deposition Author(s): Kessler, D., Zahn, S., Sanderson, M., Wolkerstorfer, B.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.264 Å
• R-Value Free: 0.262 
• R-Value Work: 0.213 

Literature

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.

Sanderson, M.P., Apgar, J., Garin-Chesa, P., Hofmann, M.H., Kessler, D., Quant, J., Savchenko, A., Schaaf, O., Treu, M., Tye, H., Zahn, S.K., Zoephel, A., Haaksma, E., Adolf, G.R., Kraut, N.

(2015) Mol.Cancer Ther. 14: 2762-2772

• PubMed: 26438154 
• DOI: 10.1158/1535-7163.MCT-15-0539


• PubMed Abstract: 
  

Inhibition of the IGF1R, INSRA, and INSRB receptor tyrosine kinases represents an attractive approach of pharmacologic intervention in cancer, owing to the roles of the IGF1R and INSRA in promoting cell proliferation and survival. However, the central role of the INSRB isoform in glucose homeostasis suggests that prolonged inhibition of this kinase could result in metabolic toxicity. We describe here the profile of the novel compound BI 885578, a potent and selective ATP-competitive IGF1R/INSR tyrosine kinase inhibitor distinguished by rapid intestinal absorption and a short in vivo half-life as a result of rapid metabolic clearance. BI 885578, administered daily per os, displayed an acceptable tolerability profile in mice at doses that significantly reduced the growth of xenografted human GEO and CL-14 colon carcinoma tumors. We found that treatment with BI 885578 is accompanied by increases in circulating glucose and insulin levels, which in turn leads to compensatory hyperphosphorylation of muscle INSRs and subsequent normalization of blood glucose within a few hours. In contrast, the normalization of IGF1R and INSR phosphorylation in GEO tumors occurs at a much slower rate. In accordance with this, BI 885578 led to a prolonged inhibition of cell proliferation and induction of apoptosis in GEO tumors. We propose that the remarkable therapeutic window observed for BI 885578 is achieved by virtue of the distinctive pharmacokinetic properties of the compound, capitalizing on the physiologic mechanisms of glucose homeostasis and differential levels of IGF1R and INSR expression in tumors and normal tissues.

---

Organizational Affiliation: 

Boehringer Ingelheim RCV GmbH & Co KG, Department of Pharmacology, Dr. Boehringer-Gasse, Vienna, Austria. [e-mail].

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Insulin receptor	A	308	Homo sapiens	Mutation(s): 0  Gene Names: INSR EC: 2.7.10.1
Find proteins for P06213 (Homo sapiens) Go to Gene View: INSR Go to UniProtKB:  P06213

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
5JA	A	(5R)-N-(1-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethyl}-1H-pyrazol-3-yl)-5,8-dimethyl-9-phenyl-6,8-dihydro-5H-pyrazolo[3,4-h]quinazolin-2-amine C29 H37 N9 O PHQDLOFSIWRQJZ-OAQYLSRUSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.264 Å
• R-Value Free: 0.262 
• R-Value Work: 0.213 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length (Å)	Angle (°)
a = 56.550	α = 90.00
b = 70.370	β = 90.00
c = 87.850	γ = 90.00

Software Package:

Software Name	Purpose
BUSTER	refinement
Coot	model building
SCALA	data scaling
XDS	data reduction
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2015-09-30 
• Released Date: 2015-10-14 
• Deposition Author(s): Kessler, D., Zahn, S., Sanderson, M., Wolkerstorfer, B.

Revision History 

• Version 1.0: 2015-10-14
  Type: Initial release
• Version 1.1: 2015-12-16
  Type: Database references